Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1213 entries
Sorted by: Best Match Show Resources per page
Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries.

Patient preference and adherence

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M.
PMID: 25525348
Patient Prefer Adherence. 2014 Dec 12;8:1713-20. doi: 10.2147/PPA.S64709. eCollection 2014.

INTRODUCTION: Hemophilia A treatment involves replacing the deficient coagulation factor VIII. This process may involve multiple steps that might create a barrier to adherence. A new dual-chamber syringe (DCS; FuseNGo(®)) was recently introduced with the aim of simplifying reconstitution.AIM:...

Cite
Cimino E, Linari S, Malerba M, et al. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence. 2014;8:1713-20doi: 10.2147/PPA.S64709.
Cimino, E., Linari, S., Malerba, M., Halimeh, S., Biondo, F., & Westfeld, M. (2014). Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient preference and adherence, 81713-20. https://doi.org/10.2147/PPA.S64709
Cimino, Ernesto, et al. "Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries." Patient preference and adherence vol. 8 (2014): 1713-20. doi: https://doi.org/10.2147/PPA.S64709
Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence. 2014 Dec 12;8:1713-20. doi: 10.2147/PPA.S64709. eCollection 2014. PMID: 25525348; PMCID: PMC4270299.
Copy Download .nbib Format: NLM
Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma.

Experimental and therapeutic medicine

Li DY, Zhang HW, Feng QZ, Zhao H.
PMID: 25574241
Exp Ther Med. 2015 Feb;9(2):598-602. doi: 10.3892/etm.2014.2126. Epub 2014 Dec 10.

This study aimed to compare and analyze the changes in the coagulation factors in fresh frozen plasma (FFP) prior to and following leukocyte filtration and irradiation. In total, 30 bags of FFP from healthy donors were processed: One-third of...

Cite
Li DY, Zhang HW, Feng QZ, et al. Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma. Exp Ther Med. 2014;9(2):598-602doi: 10.3892/etm.2014.2126.
Li, D. Y., Zhang, H. W., Feng, Q. Z., & Zhao, H. (2015). Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma. Experimental and therapeutic medicine, 9(2), 598-602. https://doi.org/10.3892/etm.2014.2126
Li, Dai-Yu, et al. "Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma." Experimental and therapeutic medicine vol. 9,2 (2015): 598-602. doi: https://doi.org/10.3892/etm.2014.2126
Li DY, Zhang HW, Feng QZ, Zhao H. Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma. Exp Ther Med. 2015 Feb;9(2):598-602. doi: 10.3892/etm.2014.2126. Epub 2014 Dec 10. PMID: 25574241; PMCID: PMC4280960.
Copy Download .nbib Format: NLM
Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes.

Haemophilia : the official journal of the World Federation of Hemophilia

Altisent C, Martorell M, Crespo A, Casas L, Torrents C, Parra R.
PMID: 26315845
Haemophilia. 2016 Mar;22(2):218-224. doi: 10.1111/hae.12792. Epub 2015 Aug 28.

AIM: This observational study was undertaken with the aim to describe the characteristics and evaluate the outcomes of prophylactic treatment in children with severe haemophilia A (HA) treated at our centre.METHODS: Twenty-five patients aged 4-19 years with severe HA,...

Cite
Altisent C, Martorell M, Crespo A, et al. Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia. 2015;22(2):218-224doi: 10.1111/hae.12792.
Altisent, C., Martorell, M., Crespo, A., Casas, L., Torrents, C., & Parra, R. (2016). Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia : the official journal of the World Federation of Hemophilia, 22(2), 218-224. https://doi.org/10.1111/hae.12792
Altisent, C, et al. "Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes." Haemophilia : the official journal of the World Federation of Hemophilia vol. 22,2 (2016): 218-224. doi: https://doi.org/10.1111/hae.12792
Altisent C, Martorell M, Crespo A, Casas L, Torrents C, Parra R. Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia. 2016 Mar;22(2):218-224. doi: 10.1111/hae.12792. Epub 2015 Aug 28. PMID: 26315845.
Copy Download .nbib Format: NLM
Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome.

Journal of investigative medicine high impact case reports

McDow AD, Gurung A, Poola R, Fratianni C, Garfinkel M, Jakoby MG.
PMID: 28491882
J Investig Med High Impact Case Rep. 2017 Apr 10;5(2):2324709617703672. doi: 10.1177/2324709617703672. eCollection 2017.

The hallmark manifestations of Cushing's syndrome (CS) are well known, but hypercoagulability is perhaps least recognized. Patients with CS are at increased risk of both spontaneous and postoperative thromboembolism, with the significant majority of events occurring in the lower...

Cite
McDow AD, Gurung A, Poola R, et al. Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome. J Investig Med High Impact Case Rep. 2017;5(2):2324709617703672doi: 10.1177/2324709617703672.
McDow, A. D., Gurung, A., Poola, R., Fratianni, C., Garfinkel, M., & Jakoby, M. G. (2017). Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome. Journal of investigative medicine high impact case reports, 5(2), 2324709617703672. https://doi.org/10.1177/2324709617703672
McDow, Alexandria D, et al. "Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome." Journal of investigative medicine high impact case reports vol. 5,2 (2017): 2324709617703672. doi: https://doi.org/10.1177/2324709617703672
McDow AD, Gurung A, Poola R, Fratianni C, Garfinkel M, Jakoby MG. Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome. J Investig Med High Impact Case Rep. 2017 Apr 10;5(2):2324709617703672. doi: 10.1177/2324709617703672. eCollection 2017. PMID: 28491882; PMCID: PMC5405892.
Copy Download .nbib Format: NLM
The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study.

PloS one

Chen CM, Yang YH, Chang CH, Chen CC, Chen PC.
PMID: 27690229
PLoS One. 2016 Sep 30;11(9):e0164009. doi: 10.1371/journal.pone.0164009. eCollection 2016.

INTRODUCTION: Rehabilitation plays an important role in the physical health of patients with hemophilia. However, comprehensive information regarding the utilization of rehabilitation for such patients remains scarce.AIM: This population-based study aimed to examine the characteristics, trends, and most important...

Cite
Chen CM, Yang YH, Chang CH, et al. The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study. PLoS One. 2016;11(9):e0164009doi: 10.1371/journal.pone.0164009.
Chen, C. M., Yang, Y. H., Chang, C. H., Chen, C. C., & Chen, P. C. (2016). The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study. PloS one, 11(9), e0164009. https://doi.org/10.1371/journal.pone.0164009
Chen, Chien-Min, et al. "The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study." PloS one vol. 11,9 (2016): e0164009. doi: https://doi.org/10.1371/journal.pone.0164009
Chen CM, Yang YH, Chang CH, Chen CC, Chen PC. The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study. PLoS One. 2016 Sep 30;11(9):e0164009. doi: 10.1371/journal.pone.0164009. eCollection 2016. PMID: 27690229; PMCID: PMC5045205.
Copy Download .nbib Format: NLM
Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.

Journal of toxicology

Rasmussen CE, Nowak J, Larsen JM, Moore E, Bell D, Liu KC, Sorensen NS, Kappers WA, Krogh-Meibom T, Offenberg H.
PMID: 28458688
J Toxicol. 2017;2017:8496246. doi: 10.1155/2017/8496246. Epub 2017 Mar 28.

Turoctocog alfa pegol (N8-GP) is a glycoPEGylated human recombinant factor VIII for the treatment of hemophilia A. The safety profile of rFVIII, and polyethylene glycols (PEG) technology, is well-established. Conducting long-term toxicity studies in animals using human proteins can...

Cite
Rasmussen CE, Nowak J, Larsen JM, et al. Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. J Toxicol. 2017;2017:8496246doi: 10.1155/2017/8496246.
Rasmussen, C. E., Nowak, J., Larsen, J. M., Moore, E., Bell, D., Liu, K. C., Sorensen, N. S., Kappers, W. A., Krogh-Meibom, T., & Offenberg, H. (2017). Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. Journal of toxicology, 20178496246. https://doi.org/10.1155/2017/8496246
Rasmussen, Caroline E, et al. "Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat." Journal of toxicology vol. 2017 (2017): 8496246. doi: https://doi.org/10.1155/2017/8496246
Rasmussen CE, Nowak J, Larsen JM, Moore E, Bell D, Liu KC, Sorensen NS, Kappers WA, Krogh-Meibom T, Offenberg H. Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. J Toxicol. 2017;2017:8496246. doi: 10.1155/2017/8496246. Epub 2017 Mar 28. PMID: 28458688; PMCID: PMC5387834.
Copy Download .nbib Format: NLM
Immunomagnetic separation as a final purification step of liver endothelial cells.

In vitro cellular & developmental biology. Animal

Gomez DE, Hartzler JL, Corbitt RH, Nason AM, Thorgeirsson UP.
PMID: 27519745
In Vitro Cell Dev Biol Anim. 1993 Jun;29(6):451-5. doi: 10.1007/BF02639378.

We describe a fast and reproducible method that can be used as a final step in obtaining pure populations of liver endothelial cells. This method employs endothelial cell specific lectin covalently bound to magnetic polystyrene beads (Dynabeads). Evonymus europaeus...

Cite
Gomez DE, Hartzler JL, Corbitt RH, et al. Immunomagnetic separation as a final purification step of liver endothelial cells. In Vitro Cell Dev Biol Anim. 1993;29(6):451-5doi: 10.1007/BF02639378.
Gomez, D. E., Hartzler, J. L., Corbitt, R. H., Nason, A. M., & Thorgeirsson, U. P. (1993). Immunomagnetic separation as a final purification step of liver endothelial cells. In vitro cellular & developmental biology. Animal, 29(6), 451-5. https://doi.org/10.1007/BF02639378
Gomez, D E, et al. "Immunomagnetic separation as a final purification step of liver endothelial cells." In vitro cellular & developmental biology. Animal vol. 29,6 (1993): 451-5. doi: https://doi.org/10.1007/BF02639378
Gomez DE, Hartzler JL, Corbitt RH, Nason AM, Thorgeirsson UP. Immunomagnetic separation as a final purification step of liver endothelial cells. In Vitro Cell Dev Biol Anim. 1993 Jun;29(6):451-5. doi: 10.1007/BF02639378. PMID: 27519745.
Copy Download .nbib Format: NLM
Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.

Frontiers in genetics

Shovlin CL.
PMID: 25914716
Front Genet. 2015 Apr 09;6:101. doi: 10.3389/fgene.2015.00101. eCollection 2015.

Hereditary hemorrhagic telangiectasia (HHT) is mechanistically and therapeutically challenging, not only because of the molecular and cellular perturbations that generate vascular abnormalities, but also the modifications to circulatory physiology that result, and are likely to exacerbate vascular injury. First,...

Cite
Shovlin CL. Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia. Front Genet. 2015;6:101doi: 10.3389/fgene.2015.00101.
Shovlin, C. L. (2015). Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia. Frontiers in genetics, 6101. https://doi.org/10.3389/fgene.2015.00101
Shovlin, Claire L. "Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia." Frontiers in genetics vol. 6 (2015): 101. doi: https://doi.org/10.3389/fgene.2015.00101
Shovlin CL. Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia. Front Genet. 2015 Apr 09;6:101. doi: 10.3389/fgene.2015.00101. eCollection 2015. PMID: 25914716; PMCID: PMC4391027.
Copy Download .nbib Format: NLM
Malignant Hepatic Epithelioid Hemangioendothelioma with Villaret Syndrome.

Journal of clinical and experimental hepatology

Pavan H, Varghese J, Harika K, Vij M, Jayanthi V, Rela M.
PMID: 28348474
J Clin Exp Hepatol. 2017 Mar;7(1):68-70. doi: 10.1016/j.jceh.2016.09.006. Epub 2016 Sep 15.

Malignant hepatic epithelioid hemangioendothelioma is a rare, vascular tumor of the liver with peak incidence in the middle age with a female preponderance and of unknown etiology. Majority of the tumors are asymptomatic. The gold standard for diagnosis of...

Cite
Pavan H, Varghese J, Harika K, et al. Malignant Hepatic Epithelioid Hemangioendothelioma with Villaret Syndrome. J Clin Exp Hepatol. 2016;7(1):68-70doi: 10.1016/j.jceh.2016.09.006.
Pavan, H., Varghese, J., Harika, K., Vij, M., Jayanthi, V., & Rela, M. (2017). Malignant Hepatic Epithelioid Hemangioendothelioma with Villaret Syndrome. Journal of clinical and experimental hepatology, 7(1), 68-70. https://doi.org/10.1016/j.jceh.2016.09.006
Pavan, Hanchanale, et al. "Malignant Hepatic Epithelioid Hemangioendothelioma with Villaret Syndrome." Journal of clinical and experimental hepatology vol. 7,1 (2017): 68-70. doi: https://doi.org/10.1016/j.jceh.2016.09.006
Pavan H, Varghese J, Harika K, Vij M, Jayanthi V, Rela M. Malignant Hepatic Epithelioid Hemangioendothelioma with Villaret Syndrome. J Clin Exp Hepatol. 2017 Mar;7(1):68-70. doi: 10.1016/j.jceh.2016.09.006. Epub 2016 Sep 15. PMID: 28348474; PMCID: PMC5357698.
Copy Download .nbib Format: NLM
Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Damodar S, Bhat P, Balasubramaniam S.
PMID: 25332547
Indian J Hematol Blood Transfus. 2014 Sep;30:90-2. doi: 10.1007/s12288-013-0270-3. Epub 2013 May 24.

Acquired haemophilia is a very rare condition, occurring in less than 2 per million populations. This condition is caused commonly by acquired antibodies against factor VIII and rarely by antibodies against factor IX. Here we describe an extremely rare...

Cite
Damodar S, Bhat P, Balasubramaniam S. Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian J Hematol Blood Transfus. 2013;30:90-2doi: 10.1007/s12288-013-0270-3.
Damodar, S., Bhat, P., & Balasubramaniam, S. (2014). Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 3090-2. https://doi.org/10.1007/s12288-013-0270-3
Damodar, Sharat, et al. "Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 30 (2014): 90-2. doi: https://doi.org/10.1007/s12288-013-0270-3
Damodar S, Bhat P, Balasubramaniam S. Symptomatic Acquired Haemophilia Due to Circulating Antibodies Against Both Factor VIII and IX in a Non-haemophiliac Patient. Indian J Hematol Blood Transfus. 2014 Sep;30:90-2. doi: 10.1007/s12288-013-0270-3. Epub 2013 May 24. PMID: 25332547; PMCID: PMC4192245.
Copy Download .nbib Format: NLM
Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding.

Experimental hematology & oncology

Cugno M, Tedeschi A, Siboni SM, Stufano F, Depetri F, Franchi F, Griffini S, Peyvandi F.
PMID: 24926417
Exp Hematol Oncol. 2014 Jun 04;3:15. doi: 10.1186/2162-3619-3-15. eCollection 2014.

A 91-year-old woman affected with acquired Von Willebrand (VW) syndrome and intestinal angiodysplasias presented with severe gastrointestinal bleeding (hemoglobin 5 g/dl). Despite replacement therapy with VW factor/factor VIII concentrate qid, bleeding did not stop (eleven packed red blood cell...

Cite
Cugno M, Tedeschi A, Siboni SM, et al. Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Exp Hematol Oncol. 2014;3:15doi: 10.1186/2162-3619-3-15.
Cugno, M., Tedeschi, A., Siboni, S. M., Stufano, F., Depetri, F., Franchi, F., Griffini, S., & Peyvandi, F. (2014). Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Experimental hematology & oncology, 315. https://doi.org/10.1186/2162-3619-3-15
Cugno, Massimo, et al. "Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding." Experimental hematology & oncology vol. 3 (2014): 15. doi: https://doi.org/10.1186/2162-3619-3-15
Cugno M, Tedeschi A, Siboni SM, Stufano F, Depetri F, Franchi F, Griffini S, Peyvandi F. Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Exp Hematol Oncol. 2014 Jun 04;3:15. doi: 10.1186/2162-3619-3-15. eCollection 2014. PMID: 24926417; PMCID: PMC4055248.
Copy Download .nbib Format: NLM
Alpha interferon for hepatitis C virus infection in haemophilic patients.

Haemophilia : the official journal of the World Federation of Hemophilia

Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G, Lee C.
PMID: 27214222
Haemophilia. 1995 Jan;1(1):54-8. doi: 10.1111/j.1365-2516.1995.tb00040.x.

We have conducted a controlled trial in 20 haemophilic patients in which intravenous recombinant interferon alpha-2a, 3 mega units thrice weekly, was used to treat chronic hepatitis C infection. The study endpoints included complete and paritial normalization of serum...

Cite
Telfer P, Devereux H, Colvin B, et al. Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia. 1995;1(1):54-8doi: 10.1111/j.1365-2516.1995.tb00040.x.
Telfer, P., Devereux, H., Colvin, B., Hayden, S., Dusheiko, G., & Lee, C. (1995). Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia : the official journal of the World Federation of Hemophilia, 1(1), 54-8. https://doi.org/10.1111/j.1365-2516.1995.tb00040.x
Telfer, P, et al. "Alpha interferon for hepatitis C virus infection in haemophilic patients." Haemophilia : the official journal of the World Federation of Hemophilia vol. 1,1 (1995): 54-8. doi: https://doi.org/10.1111/j.1365-2516.1995.tb00040.x
Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G, Lee C. Alpha interferon for hepatitis C virus infection in haemophilic patients. Haemophilia. 1995 Jan;1(1):54-8. doi: 10.1111/j.1365-2516.1995.tb00040.x. PMID: 27214222.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1213 entries